Renal glucose reabsorption was measured with the stepped-hyperglycemic clamp in 15 T2DM and 15 non-diabetic subjects after 2 days and after more chronic (14 days) treatment with empagliflozin. T2DM patients had significantly greater maximal renal glucose transport (TmG) compared to nondiabetic subjects at baseline (459±53 vs 337±25 mg/min, p<0.05). Empagliflozin treatment for 48 hours reduced the TmG in both diabetic and non-diabetic individuals by 44±7% and 53±6%, respectively (both p<0.001). TmG was further reduced by empagliflozin in both groups on day 14 (by 65±5% and 75±3%, respectively). Empagliflozin reduced the plasma glucose concentration threshold for glucose spillage in the urine similarly in T2DM and non-diabetic individuals to less than 40 mg/dl, which is well below the normal fasting plasma glucose concentration. In summary, SGLT2 inhibition with empagliflozin reduces both TmG and threshold for glucose spillage in the urine in T2DM and non-diabetic patients.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0100/-/DC1.
- Received January 20, 2017.
- Accepted April 11, 2017.
- © 2017 by the American Diabetes Association.